Raloxifene
Raloxifene is an active ingredient of the class «selective estrogen-receptor modulators».
Chemical compound
Boxed warning (US label)
Increased risk of venous thromboembolism and death from stroke. Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA. Women with active or past history of venous thromboembolism should not take EVISTA. Increased risk of death due to stroke occurred in a trial in postmenopausal…
What it is used for
- Bone disease
- Osteoporosis
- Breast neoplasm
- Postmenopausal osteoporosis
EVISTA ® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
How it works
- Estrogen receptor beta modulator
- Estrogen receptor modulator
Class: selective estrogen-receptor modulators
Common side effects
Hot flashes occurred in about one in 10 patients on EVISTA and were most commonly reported during the first 6 months of treatment and were not different from placebo thereafter.
Who should not take it
Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
Pregnancy and breastfeeding
EVISTA is contraindicated for use in pregnant women, and is not indicated for use in females of reproductive potential. Based on mechanism of action, EVISTA may block the important functions that estrogen has during all stages of pregnancy.
Interactions
Brand names
United States
Evista
European Union
Evista
Canada
ACT Raloxifene · Apo-Raloxifene · Jamp Raloxifene
Other trade names
Evirex · Optruma · Ostiral · Razylan
Approval status
- US Food and Drug Administration
- prescription · since 1997
- European Medicines Agency
- authorised · since 1998
- Health Canada
- prescription · marketed
- First approval anywhere
- 1997
Codes
- ATC
- G03XC01
- RxNorm CUI
- 72143
- ChEMBL
- CHEMBL81
- PubChem CID
- 5035
- UNII
- YX9162EO3I
- Wikidata
- Q425223
Frequently asked questions
What is Raloxifene used for?
Raloxifene is used for: Bone disease, Osteoporosis, Breast neoplasm, and Postmenopausal osteoporosis.
What kind of medicine is Raloxifene?
Raloxifene is an active ingredient of the class «selective estrogen-receptor modulators».
What are the brand names of Raloxifene?
Brand names of Raloxifene include Evista, ACT Raloxifene, Apo-Raloxifene, Jamp Raloxifene, Evirex, Optruma, Ostiral, and Razylan.
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)